Avita Medical
RCEL
Avita Medical (RCEL) - P/B ratio
P/B ratio as of June 2024 : 6.29
According to Avita Medical
's latest financial reports the company has a price-to-book ratio of 6.29.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Avita Medical - P/B ratio (from 2020 to 2019)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2024-12-31 | N/A | -100% |
| 2023-12-31 | 7.15 | 266.55% |
| 2022-12-31 | 1.95 | -27.21% |
| 2021-12-31 | 2.68 | -60.27% |
| 2020-12-31 | 6.74 | -91.5% |
| 2019-12-31 | 79.3 | 165.9% |
| 2018-12-31 | 29.8 | -6.23% |
| 2017-12-31 | 31.8 | -48.23% |
| 2016-12-31 | 61.5 | 26.53% |
| 2015-12-31 | 48.6 | -37.25% |
| 2014-12-31 | 77.4 | 90% |
| 2013-12-31 | 40.7 | 177.32% |
| 2012-12-31 | 14.7 | 619.18% |
| 2011-12-31 | 2.04 | |
| 2010-12-31 | N/A | |
| 2009-12-31 | N/A | -100% |
| 2008-12-31 | 0.4449 | -62.45% |
| 2007-12-31 | 1.18 | |
| 2006-12-31 | N/A | |
| 2005-12-31 | N/A | -100% |
| 2004-12-31 | 4.93 | -7.57% |
| 2003-12-31 | 5.34 | |
| 2002-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Organovo ONVO | 2.99 | -52.41% | 🇺🇸 USA |
 Orchard Therapeutics
ORTX | 4.74 | -24.70% | 🇬🇧 UK |
 Novavax NVAX | -2.38 | -137.81% | 🇺🇸 USA |
 Novocure
NVCR | 5.40 | -14.11% | Jersey |